Certuity’s Ultragenyx Pharmaceutical RARE Stock Holding History

Certuity’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,145	Closed	-$437K	–	369
2023 Q4	$437K	Buy	+9,145	New	+$355K	0.04%	197

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Certuity's RARE Position: Q1 2024 in Review

Certuity sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2024, closing a stake of 9,145 shares — an estimated $437K sold.

Certuity first reported a position in RARE in Q4 2023 and held it in 1 quarter. The position peaked at $437K in Q4 2023. 269 funds tracked by Wall St. Rank hold RARE as of Q1 2024.

Certuity reported no remaining Ultragenyx Pharmaceutical position as of Q1 2024 after selling out during the quarter.
Certuity sold 9,145 Ultragenyx Pharmaceutical shares in Q1 2024, an estimated $437K.
Certuity first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 1 quarter.
Certuity's Ultragenyx Pharmaceutical position peaked at $437K in Q4 2023.
269 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2024.

Based on Certuity's 13F filing for Q1 2024, filed 15 May 2024.